There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zevra Therapeutics (ZVRA – Research Report), ALX Oncology Holdings (ALXO – Research Report) and Quoin Pharmaceuticals (QNRX – Research Report) with bullish sentiments.
Zevra Therapeutics (ZVRA)
In a report released yesterday, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Zevra Therapeutics, with a price target of $24.00. The company’s shares closed last Friday at $4.96.
According to TipRanks.com, Kulkarni is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zevra Therapeutics with a $19.00 average price target, which is a 283.8% upside from current levels. In a report issued on May 8, Maxim Group also reiterated a Buy rating on the stock with a $18.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
ALX Oncology Holdings (ALXO)
LifeSci Capital analyst Sam Slutsky maintained a Buy rating on ALX Oncology Holdings today and set a price target of $19.00. The company’s shares closed last Friday at $16.34, close to its 52-week high of $17.83.
According to TipRanks.com, Slutsky is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ALX Oncology Holdings with a $20.80 average price target, representing a 18.9% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $25.00 price target.
Quoin Pharmaceuticals (QNRX)
Maxim Group analyst Naz Rahman maintained a Buy rating on Quoin Pharmaceuticals yesterday and set a price target of $4.00. The company’s shares closed last Friday at $0.79, close to its 52-week low of $0.60.
According to TipRanks.com, Rahman has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Quoin Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $7.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ZVRA:
- Zevra Therapeutics sees cash, equivalents extending cash runway into 2026
- Zevra Therapeutics reports Q1 EPS (40c), consensus (48c)
- Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
- Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024
- Zevra Therapeutics issues letter to stockholders on recent accomplishments
